الولايات المتحدة · منصات وبيانات · MarketBeat

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

نشره MarketBeat · الولايات المتحدة منذ 2 س

Amgen (NASDAQ:AMGN) presented Phase III data at the European Society for Medical Oncology Congress 2026 showing that its DLL3-targeting BiTE therapy IMDELLTRA, when added to…

اقرأ المقال كاملًا على MarketBeat سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.marketbeat.com)

يستحق القراءة أيضًا

The Motley Fool

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Yahoo Finance

Hercules Capital (HTGC) Stock Still Looks Undervalued After A 63% Five Year Run

TheStreet

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

مشاركة

يستحق القراءة أيضًا

1 Red Flag That Keeps Me From Buying AMD Stock

Yemen’s Houthis renew threat against Riyadh airport as flights set to resume

Musk says Ukraine violated Starlink terms with offensive drone strikes

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Hercules Capital (HTGC) Stock Still Looks Undervalued After A 63% Five Year Run

Bank of America resets Tesla forecast as Robotaxi miles double